Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit

Aug 27 2020

• By Joseph Haas

DATA_Puzzle Piece_186976547_1200.jpg — Companies presented new data in NASH and PBC at EASL 2020

Related Content

CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Nov 25 2019

CymaBay’s Stalled Seladelpar Back In Play For PBC

Aug 03 2020

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

No Read-Through Expected: NASH Field Unfazed By Intercept’s FDA Rejection

Jul 03 2020

Axcella Addresses Metabolic Disease Quickly With GRAS Candidates

Feb 19 2020

Related Companies

Intercept Pharmaceuticals, Inc.

Axcella Therapeutics, Inc.

CymaBay Therapeutics, Inc.

Additional Topics

Clinical Trials Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window